Bravecto PLUS for Medium Cats (2.8-6.25kg)

Active Ingredients
Bravecto contains fluralaner.

Indications: For the control of flea and tick infestations on cats for 3 months

• Treats and controls existing flea and tick infestations
• Sustained control of new flea and tick infestations
• Part of a treatment strategy for the control of flea allergy dermatitis
• Highly effective against fipronil resistant fleas
• For cats suffering from, or at risk from, mixed ecto- and endoparasitic infections
• Treatment of infections with intestinal roundworm (Toxocara cati, Toxacaris leonine; 4^th stage larvae, immature adults and adults), lungworm (Aelurostrongylus obstrusus) and Capillaria spp.
• Treatment of Otodectes cynotis spp. mites

Dosage
Bravecto Plus spot-on solution* should be administered in accordance with the following table (corresponding to a dose of 40 – 94 mg fluralaner/kg body weight + 2 – 4.7 moxidectin/kg body weight):

*For use in cats from 9 weeks of age and over 1.2kg.

For optimal control of tick and flea infestation, the Bravecto Plus * should be administered at 3 monthly intervals. Bravecto Plus* can be administered all year round.Bravecto Plus spot-on solution for cats provides 3 months flea and tick protection plus a comprehensive worm treatment in a single spot-on.

Why choose Bravecto Plus for your cat:

• Long lasting, all-in-one parasite protection for cats. With parasite treatment including fleas, ticks, roundworm, lungworm and ear mites.
• Treat every 3 months for fleas, ticks and worms. Less frequent dosing makes it easier to treat cats.
• Peace of mind parasite protection with fewer doses than monthly alternatives. Only 4 doses a year.
• Rapid onset of action and long lasting protection against fleas on your cat with no viable egg production.
• Effective against ear mites after a single treatment.
• Twist-n-use tube makes application easy and convenient.
• Available for cats in 3 weight ranges from 1.2 to 12.5 kg.

New Zealand’s No. 1 parasite treatment for cats, (Baron Industry data, March 2022).